title: Effect of an inhaled glucocorticosteroid on airway mucosal blood flow in mild asthma.
abstract: We determined airway mucosal blood flow (Qaw) and FEV (1) before and after inhaled albuterol in 19 glucocorticosteroid (GS)-naive patients with mild intermittent asthma, and assessed the effects of a 2-wk course of fluticasone propionate (FP; 440 microg daily) on these parameters. Twelve healthy nonsmokers served as controls. Baseline Qaw was 55.5 +/- 0.7 microl/min/ml (mean +/- SE) in the asthmatic subjects and 44.2 +/- 0.7 microl/min/ml in the controls; the respective FEV(1) values were 2.8 +/- 0.2 L and 3.4 +/- 0.2 L (p < 0.01 for both parameters). Albuterol increased Qaw by 27 +/- 3% in the control subjects (p < 0.01) but had no effect on Qaw in the asthmatic subjects; it increased FEV (1) by 7 +/- 1% and 6 +/- 1% in the two groups, respectively. Qaw decreased to 49.2 +/- 0.8 microl/min/ml (p < 0.05 versus baseline), and the Qaw responsiveness to albuterol was restored ( +21 +/- 2%; p < 0.05) in the asthmatic subjects after FP. Eleven asthmatic subjects stopped using FP at this time; 2 wk later, their Qaw returned to baseline (55.2 +/- 0.9 microl/min/ml) and they lost the Qaw responsiveness to albuterol. Mean ( +/- SE) FEV(1) and FEV(1) responsiveness to albuterol were not affected by FP. The GS-sensitive increase in Qaw and its hyporesponsiveness to albuterol in asthmatic subjects may be consequences of airway inflammation.
authors.affiliation: Division of Pulmonary and Critical Care Medicine, University of Miami School of Medicine, Miami, Florida 33101, USA.
authors.forename: J L
authors.initials: JL
authors.lastname: Brieva
authors.forename: I
authors.initials: I
authors.lastname: Danta
authors.forename: A
authors.initials: A
authors.lastname: Wanner
mesh_terms: D000280:Administration, Inhalation; D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000420:Albuterol / Q000008:administration & dosage / Q000627:therapeutic use; D000730:Androstadienes / Q000008:administration & dosage* / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy / Q000503:physiopathology*; D001783:Blood Flow Velocity / Q000187:drug effects; D001980:Bronchi / Q000098:blood supply*; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002196:Capillaries / Q000187:drug effects / Q000503:physiopathology; D004359:Drug Therapy, Combination; D005260:Female; D000068298:Fluticasone; D005541:Forced Expiratory Volume / Q000187:drug effects; D005938:Glucocorticoids; D006801:Humans; D008297:Male; D008875:Middle Aged; D009092:Mucous Membrane / Q000098:blood supply; D011446:Prospective Studies; D011652:Pulmonary Circulation / Q000187:drug effects; D014661:Vasoconstriction / Q000187:drug effects
chemical_list: D000730:Androstadienes; D000893:Anti-Inflammatory Agents; D001993:Bronchodilator Agents; D005938:Glucocorticoids; D000068298:Fluticasone; D000420:Albuterol